HKSE - Delayed Quote HKD

WuXi XDC Cayman Inc (2268.HK)

20.500 +0.500 (+2.50%)
At close: April 26 at 4:08 PM GMT+8
Key Events
Loading Chart for 2268.HK
DELL
  • Previous Close 20.000
  • Open 20.400
  • Bid 20.500 x --
  • Ask 20.600 x --
  • Day's Range 19.820 - 20.900
  • 52 Week Range 12.080 - 34.000
  • Volume 2,757,509
  • Avg. Volume 3,562,716
  • Market Cap (intraday) 24.551B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 73.21
  • EPS (TTM) 0.280
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 31.00

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

wuxixdc.com

1,178

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 2268.HK

Performance Overview: 2268.HK

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

2268.HK
35.94%
HANG SENG INDEX
3.54%

1-Year Return

2268.HK
--
HANG SENG INDEX
1.13%

3-Year Return

2268.HK
--
HANG SENG INDEX
1.13%

5-Year Return

2268.HK
--
HANG SENG INDEX
1.13%

Compare To: 2268.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 2268.HK

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    24.55B

  • Enterprise Value

    20.18B

  • Trailing P/E

    72.96

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.63

  • Price/Book (mrq)

    4.17

  • Enterprise Value/Revenue

    9.50

  • Enterprise Value/EBITDA

    56.00

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.35%

  • Return on Assets (ttm)

    4.95%

  • Return on Equity (ttm)

    8.18%

  • Revenue (ttm)

    2.12B

  • Net Income Avi to Common (ttm)

    283.54M

  • Diluted EPS (ttm)

    0.280

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.05B

  • Total Debt/Equity (mrq)

    0.05%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 2268.HK

Analyst Price Targets

18.33
31.00 Average
20.500 Current
42.79 High
 

Fair Value

 

Company Insights: 2268.HK

People Also Watch